XML 43 R22.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table sets forth information about the Company’s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to net loss (in thousands):

Three Months Ended March 31,
20262025
Revenue$— $— 
Operating expenses:
Research and development:
SL-3251
2,861 2,229 
Other research and development2,3
4,667 4,606 
Research and development non-equity compensation2,382 2,397 
Research and development equity compensation1,036 687 
Total research and development10,946 9,919 
General and administrative expenses:
General and administrative non-equity compensation1,427 1,353 
General and administrative equity compensation1,379 1,033 
Other general and administrative including legal and accounting fees, facilities, insurance, travel and depreciation1,793 2,084 
Total general and administrative4,599 4,470 
Expense from operations
15,545 14,389 
Loss from operations(15,545)(14,389)
Other Income
778687 
Net Loss$(14,767)$(13,702)
1 Expenses for SL-325 that were incurred prior to it being nominated a product candidate are included in “other research and development”.
2 Other research and development expense includes technical operations expense of $1.9 million and $2.4 million, research activities for other pipeline compounds and facility expenses of $1.9 million and $1.3 million and depreciation expense of $0.9 million and $0.9 million for the three months ended March 31, 2026 and 2025, respectively.
3 Other research and development expense includes a gain of $0.7 million due to a change in estimate and expense of $2.0 million for the three months ended March 31, 2026 and 2025, respectively, related to SL-172154 which was discontinued in October 2024.